Generic Adzenys ER Availability
Last updated on Apr 10, 2025.
See also: Generic Adzenys XR-ODT
Adzenys ER is a brand name of amphetamine, approved by the FDA in the following formulation(s):
ADZENYS ER (amphetamine - suspension, extended release;oral)
-
Manufacturer: NEOS THERAPS INC
Approval date: September 15, 2017
Strength(s): EQ 1.25MG BASE/ML (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Adzenys ER. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Patent 8,709,491
Issued: April 29, 2014
Inventor(s): Tengler Mark & McMahen Russell
Assignee(s): NEOS Terapeutics, LPThe invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. In a particular embodiment, the drug dosage form comprises a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.
Patent expiration dates:
- June 28, 2032✓
- June 28, 2032
-
Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles
Patent 9,017,731
Issued: April 28, 2015
Inventor(s): Tengler Mark & McMahen Russell
Assignee(s): Neos Therapeutics, LPThe invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. In a particular embodiment, the drug dosage form comprises a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms.
Patent expiration dates:
- June 28, 2032✓
- June 28, 2032
-
Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles
Patent 9,265,737
Issued: February 23, 2016
Inventor(s): Tengler Mark & McMahen Russell
Assignee(s): NEOS THERAPEUTICS, LPThe invention relates to a pharmaceutical composition comprising amphetamines complexed with ion-exchanged resin particles to form drug-resin particles. The composition provides for prolonged therapy.
Patent expiration dates:
- June 28, 2032✓
- June 28, 2032
More about Adzenys ER (amphetamine)
- Adzenys ER consumer information
- Check interactions
- Compare alternatives
- Reviews (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CNS stimulants
- Breastfeeding
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.